Ikaria Holdings to Pay $285 Million for BioLine Drug License  
7/6/2009 7:34:20 AM

Bookmark and Share

Reuters -- Israeli drug development company BiolineRX (BLRX.TA) said on Monday that New Jersey-based Ikaria Holdings Inc had agreed to pay $285 million for a license to develop and market its BL-1040 drug for heart attack patients.